Déjà vu for Zafgen: Still fretting about lingering cardio concerns, FDA clamps a hold on lead obesity drug -- shares plunge
Two years after Zafgen torched its lead obesity compound following an ugly crash in late-stage testing that cost lives, the FDA is still fretting whether the company is continuing to expose more people to harm.
The biotech reported today that the FDA has slapped a clinical hold on their MetAP2 drug ZGN-1061, worried that the cardio threat posed by their first-gem drug beloranib might still be in play. They plan to follow up with a face-to-face meeting, but there’s no clarity on how long their drug could be in limbo now.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
